Accessibility Menu
Revelation Biosciences logo

Revelation Biosciences

(NASDAQ) REVB

Current Price$1.08
Market Cap$4.06M
Since IPO (2020)-100%
5 Year-100%
1 Year-88%
1 Month+2%

Revelation Biosciences Financials at a Glance

Market Cap

$4.06M

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.87M

EPS (TTM)

-$39.47

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$1.08

Volume

103,234

Open

$1.08

Previous Close

$1.08

Daily Range

$1.05 - $1.11

52-Week Range

$0.88 - $12.88

Estimated Earnings Date

Aug 7, 2026

REVB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Revelation Biosciences

Industry

Biotechnology

Employees

8

CEO

James M. Rolke

Headquarters

San Diego, CA 92122, US

REVB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-107.66%

Return on Capital

-94.41%

Return on Assets

-65.62%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.06M

Shares Outstanding

3.91M

Volume

103.23K

Avg. Volume

61.16K

Financials (TTM)

Gross Profit

-$27.04K

Operating Income

-$10.07M

EBITDA

-$10.04M

Operating Cash Flow

-$8.69M

Capital Expenditure

-$71.88K

Free Cash Flow

-$8.76M

Cash & ST Invst.

$14.11M

Total Debt

$759.04K

Revelation Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$7.20K

+0.2%

Gross Margin

0.00%

N/A

Market Cap

$4.06M

N/A

Market Cap/Employee

$508.10K

N/A

Employees

8

N/A

Net Income

-$3.01M

-46.7%

EBITDA

-$3.09M

-47.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.11M

+281.0%

Total Debt

$759.04K

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$638.18K

N/A

Short Term Debt

$120.86K

N/A

Return on Assets

-65.62%

N/A

Return on Invested Capital

-73.88%

N/A

Free Cash Flow

-$3.29M

-17.6%

Operating Cash Flow

-$3.21M

-15.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
GTBPGT Biopharma, Inc.
$0.47-4.49%
INDPIndaptus Therapeutics, Inc.
$3.03+3.06%
SLXNSilexion Therapeutics Ltd.
$2.65+2.32%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.92-0.01%
TAT&T
$20.58+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.30-0.15%
CLROClearOne
$6.48+1.01%

Questions About REVB

What is the current price of Revelation Biosciences?

Revelation Biosciences is trading at $1.08 per share.

What is the 52-week range for Revelation Biosciences?

Over the past 52 weeks, Revelation Biosciences has traded between $0.88 and $12.88.

How much debt does Revelation Biosciences have?

As of the most recent reporting period, Revelation Biosciences reported total debt of $759.04K.

How much cash does Revelation Biosciences have on hand?

Revelation Biosciences reported $14.11M in cash and cash equivalents in its most recent financial results.

What is Revelation Biosciences’s dividend yield?

Revelation Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.